Givosiran

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 130 publications

Biochemically Evolving Acute Hepatic Porphyria With Postpartum Progression to Severe Recurrent Neurovisceral Disease.

Biochemically Evolving Acute Hepatic Porphyria With Postpartum Progression to Severe Recurrent Neurovisceral Disease.

Journal: Cureus
Published: May 28, 2026

Advanced Management of Acute Intermittent Porphyria: The Role of Givosiran Therapy in Improving Long-Term Outcomes-A Case Study.

Advanced Management of Acute Intermittent Porphyria: The Role of Givosiran Therapy in Improving Long-Term Outcomes-A Case Study.

Journal: Clinical case reports
Published: May 04, 2026

Pancreatitis Associated With Givosiran: A Real-World Pharmacovigilance Study Based on the FAERS and EudraVigilance Databases.

Pancreatitis Associated With Givosiran: A Real-World Pharmacovigilance Study Based on the FAERS and EudraVigilance Databases.

Journal: Clinical therapeutics
Published: April 11, 2026

Acute intermittent porphyria presenting with rhabdomyolysis and polyneuropathy with severe quadriparesis and respiratory failure: A case report.

Acute intermittent porphyria presenting with rhabdomyolysis and polyneuropathy with severe quadriparesis and respiratory failure: A case report.

Journal: World journal of critical care medicine
Published: March 11, 2026

Real-World Experience With Givosiran in Acute Porphyrias: A Narrative Review and a Novel Hypothesis.

Real-World Experience With Givosiran in Acute Porphyrias: A Narrative Review and a Novel Hypothesis.

Journal: Cureus
Published: March 02, 2026

Adverse events of givosiran in the treatment of acute hepatic porphyria: a pharmacovigilance study using the FAERS and VigiAccess databases.

Adverse events of givosiran in the treatment of acute hepatic porphyria: a pharmacovigilance study using the FAERS and VigiAccess databases.

Journal: Orphanet journal of rare diseases
Published: January 30, 2026

A computational model-powered platform to inform the development of GalNAc-conjugated siRNA therapeutics.

A computational model-powered platform to inform the development of GalNAc-conjugated siRNA therapeutics.

Journal: Molecular therapy. Nucleic acids
Published: December 19, 2025

Class-Specific Adverse Events of Patients Treated with Small Interfering RNA Therapeutics: A Disproportionality Analysis of the United States Food and Drug Administration Adverse Event Reporting System Database Based on the MY FAERS Platform.

Class-Specific Adverse Events of Patients Treated with Small Interfering RNA Therapeutics: A Disproportionality Analysis of the United States Food and Drug Administration Adverse Event Reporting System Database Based on the MY FAERS Platform.

Journal: Nucleic acid therapeutics
Published: November 22, 2025

Acute intermittent porphyria: When diagnostic errance jeopardizes patient health

Acute intermittent porphyria: When diagnostic errance jeopardizes patient health

Journal: La Revue de medecine interne
Published: November 07, 2025

Treating a patient with ADP porphyria through suppression of both hepatic and erythroid ALA production.

Treating a patient with ADP porphyria through suppression of both hepatic and erythroid ALA production.

Journal: Orphanet journal of rare diseases
Published: October 08, 2025

Small RNA or oligonucleotide drugs and challenges in evaluating drug-drug interactions.

Small RNA or oligonucleotide drugs and challenges in evaluating drug-drug interactions.

Journal: Frontiers in pharmacology
Published: October 07, 2025

Patient-centered and coordinated therapy with RNA interference-based givosiran for acute hepatic porphyria: real-life experience for an ultra-rare disease from Romania.

Patient-centered and coordinated therapy with RNA interference-based givosiran for acute hepatic porphyria: real-life experience for an ultra-rare disease from Romania.

Journal: Blood science (Baltimore, Md.)
Published: September 23, 2025
Showing 1-12 of 130

Last Updated: 09/26/2026